This characteristic pattern of expression allowed CD1a to present as a fratricide-resistant target for CAR-T therapy with robust tumoricidal activity and considerable persistence against CD1a-expressing T-ALL cell lines and primary cells of cortical T-ALL samples [73]. The gene discussed is CD1A; the disease is acute lymphoblastic leukemia.